盐酸埃克替尼的药理学及临床研究进展

Progression of pharmacology and clinical study of icotinib hydrochloride

非小细胞肺癌（ NSCLC）约占肺癌的80％～85％。晚期NSCLC主要以内科治疗为主，既往主要应用化疗，但疗效差。近年来，表皮生长因子受体酪氨酸激酶抑制剂（ EGFR-TKI）的应用为NSCLC的治疗提出了新的突破。盐酸埃克替尼作为一种国产的EGFR-TKI，其临床前期研究及其临床研究均显示其较好的安全性、耐受性和疗效，为晚期NSCLC治疗的新选择。

Non-small cell lung cancer （ NSCLC ） accounts for about 80%-85% of lung cancer. The main treatment of advanced NSCLC is medical treatment such as chemotherapy which shows poor efficacy. Recently, epidermal growth factor receptor-tyrosine kinase inhibitor （ EGFR-TKI） in the treatment of patients with advanced NSCLC has made a new breakthrough. Icotinib as a domestic EGFR-TKI, preclinical studies and clinical studies show that it has promising safety, tolerability and efficacy in patients with advanced NSCLC.